DE69501817D1 - Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten - Google Patents

Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten

Info

Publication number
DE69501817D1
DE69501817D1 DE69501817T DE69501817T DE69501817D1 DE 69501817 D1 DE69501817 D1 DE 69501817D1 DE 69501817 T DE69501817 T DE 69501817T DE 69501817 T DE69501817 T DE 69501817T DE 69501817 D1 DE69501817 D1 DE 69501817D1
Authority
DE
Germany
Prior art keywords
treating
ige antagonists
parasital
infections
parasital infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69501817T
Other languages
English (en)
Other versions
DE69501817T2 (de
Inventor
Payman Amiri
Mary Haak-Frendscho
Paula Jardieu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69501817D1 publication Critical patent/DE69501817D1/de
Publication of DE69501817T2 publication Critical patent/DE69501817T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69501817T 1994-01-18 1995-01-05 Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten Expired - Fee Related DE69501817T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18408394A 1994-01-18 1994-01-18
PCT/US1995/000087 WO1995019181A1 (en) 1994-01-18 1995-01-05 A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS

Publications (2)

Publication Number Publication Date
DE69501817D1 true DE69501817D1 (de) 1998-04-23
DE69501817T2 DE69501817T2 (de) 1998-09-10

Family

ID=22675480

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69501817T Expired - Fee Related DE69501817T2 (de) 1994-01-18 1995-01-05 Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten

Country Status (10)

Country Link
US (1) US5656273A (de)
EP (1) EP0739214B1 (de)
JP (1) JP3825798B2 (de)
AP (1) AP660A (de)
AT (1) ATE164079T1 (de)
DE (1) DE69501817T2 (de)
DK (1) DK0739214T3 (de)
MX (1) MX9602818A (de)
PH (1) PH31447A (de)
WO (1) WO1995019181A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL137649A (en) * 1998-02-18 2004-08-31 Genentech Inc Method of adsorption chromatography
AU6254799A (en) * 1998-09-16 2000-04-03 Tanox, Inc. Anti-ige gene therapy
EP1113818B1 (de) * 1998-09-18 2006-05-17 Dynavax Technologies Corporation Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
WO2002092125A1 (en) * 2001-05-11 2002-11-21 Novartis Ag Compositions for use in treating ige-associated disorders
WO2002094228A1 (en) * 2001-05-23 2002-11-28 David Follansbee Prevention and treatment of allergies by helminthic regulation of ige
EP2048154B2 (de) 2002-02-05 2015-06-03 Genentech, Inc. Proteinreinigung
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
ES2466716T3 (es) * 2002-11-08 2014-06-11 Ablynx N.V. Anticuerpos de un solo dominio estabilizados
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
WO2004041865A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
DK3095793T3 (da) 2003-07-28 2020-05-25 Genentech Inc Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
WO2005105106A2 (en) * 2004-04-21 2005-11-10 Roby Russell R Hormone treatment of macular degeneration
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2007172129A (ja) * 2005-12-20 2007-07-05 Sony Corp 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US20110105559A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy
US20110104159A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
CA2661197C (en) * 2006-09-11 2012-01-03 Bausch & Lomb Incorporated Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
WO2008079302A2 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
NZ577933A (en) 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
RU2498991C2 (ru) 2007-10-30 2013-11-20 Дженентек, Инк. Очистка антител с помощью катионообменной хроматографии
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
EP3604324B1 (de) 2008-08-14 2024-02-28 Genentech, Inc. Verfahren zur entfernung einer verunreinigung unter verwendung von ionenaustauschmembranchromatografie mit verschiebung ansässiger proteine
EP2684570A1 (de) 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Zusammensetzungen und Verfahren zur Prävention des oxidativen Abbaus von Proteinen
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
SG171446A1 (en) 2008-12-16 2011-07-28 Millipore Corp Stirred tank reactor and method
EP2400992B1 (de) 2009-02-27 2015-07-22 Genentech, Inc. Verfahren und zusammensetzungen zur kennzeichnung von proteinen
SG10201901417UA (en) 2009-08-11 2019-03-28 Genentech Inc Production of proteins in glutamine-free cell culture media
KR101764449B1 (ko) 2009-09-01 2017-08-02 제넨테크, 인크. 변형된 단백질 ａ 용리를 통한 증진된 단백질 정제
CA2792125C (en) 2010-03-22 2019-02-12 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
CN102892791B (zh) 2010-05-17 2017-05-17 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
RU2614125C2 (ru) 2010-05-28 2017-03-22 Дженентек, Инк. Снижение уровня лактата и увеличение продукции полипептида путем ингибирования экспрессии лактатдегидрогеназы и киназы пируватдегидрогеназы
SG186783A1 (en) 2010-06-24 2013-02-28 Genentech Inc Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
CA2808185A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1.beta. and il-18, for treatment of disease
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
KR101949187B1 (ko) 2011-07-08 2019-04-22 이엠디 밀리포어 코포레이션 일회용 생명공학적 공정용의 개선된 심층 필터
TR201815709T4 (tr) 2011-12-22 2018-11-21 Hoffmann La Roche İyon değişim membranı kromatografisi.
EP2831261B1 (de) 2012-03-27 2017-10-18 F. Hoffmann-La Roche AG Verfahren zur Herstellung von rekombinanter Proteinen mit niedrigem Gehalt an DHNA (1,4-Dihydroxy-2-Naphthoate)
SG10201709555SA (en) 2012-05-18 2017-12-28 Genentech Inc High-concentration monoclonal antibody formulations
CN104994885B (zh) 2012-12-19 2017-09-29 基因泰克公司 用于放射性卤素蛋白质标记的方法和组合物
BR112017000142B1 (pt) 2014-07-09 2021-08-17 Genentech, Inc Métodos para melhorar a recuperação por descongelamento de bancos de células e para congelamento de células cho para armazenamento, grupo de células cho para o congelamento de células de mamíferos, e banco de células
MX2018011834A (es) 2016-03-29 2019-03-06 Geltor Inc Expresión de proteínas en bacterias gram negativas en la que la relación del volumen periplasmático con respecto al volumen citoplasmático está entre 0.5:1 y 10:1.
JP2020503316A (ja) 2016-12-22 2020-01-30 ジェネンテック， インコーポレイテッド 凍結乾燥ポリペプチドの再構成時間を低減するための方法及び製剤
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
CA3104684A1 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Methods of producing recombinant proteins
KR20210074341A (ko) 2018-10-10 2021-06-21 베링거 인겔하임 인터내셔날 게엠베하 고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
CA3133652A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CN113993885A (zh) 2019-04-12 2022-01-28 格尔托公司 重组弹性蛋白及其生产
KR20220039777A (ko) 2019-08-01 2022-03-29 브리스톨-마이어스 스큅 컴퍼니 유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
JP2023542924A (ja) 2020-09-22 2023-10-12 ブリストル－マイヤーズ スクイブ カンパニー 治療タンパク質を生産するための方法
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946788A (en) * 1985-06-11 1990-08-07 Ciba-Geigy Corporation Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications
US4714759A (en) * 1985-12-02 1987-12-22 Whitaker Jr Robert B Immunotoxin therapy of allergy
US4940782A (en) * 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
US4962035A (en) * 1987-12-01 1990-10-09 President And Fellows Of Harvard College DNA encoding IgE receptor alpha-subunit or fragment thereof
US5252467A (en) * 1987-12-31 1993-10-12 Tanox Biosystems, Inc. Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE
US5091313A (en) * 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
DE122006000007I1 (de) * 1987-12-31 2006-04-27 Tanox Biosystems Inc Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden.
JP2988635B2 (ja) * 1990-09-18 1999-12-13 塩野義製薬株式会社 ヒトＩｇＥに対するモノクローナル抗体
EP0602126B1 (de) * 1991-08-14 2003-03-05 Genentech, Inc. Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner

Also Published As

Publication number Publication date
MX9602818A (es) 1997-06-28
PH31447A (en) 1998-11-03
EP0739214A1 (de) 1996-10-30
AP9600875A0 (en) 1997-01-31
AP660A (en) 1998-08-18
DK0739214T3 (da) 1998-10-07
JPH10503749A (ja) 1998-04-07
US5656273A (en) 1997-08-12
ATE164079T1 (de) 1998-04-15
WO1995019181A1 (en) 1995-07-20
EP0739214B1 (de) 1998-03-18
DE69501817T2 (de) 1998-09-10
JP3825798B2 (ja) 2006-09-27

Similar Documents

Publication Publication Date Title
DE69501817T2 (de) Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
DE69620848D1 (de) Photolack-Entfernungslösung und Verfahren zur Entfernung von Photolack unter Verwendung derselben
DE69331469D1 (de) Verfahren zur behandlung von abfällen
DE69427826T2 (de) Verfahren und system zur reinigung von bohrlöchern
DE69624116T2 (de) Verfahren zur behandlung von allergischem asthma
DE69603255D1 (de) Verfahren zur modifizierung von oberflächen
DE59401597D1 (de) Verfahren zur Überwachung von beweglichen Elementen
DE69603838D1 (de) Verfahren zur behandlung von gasen
DE69507500D1 (de) Verfahren zur behandlung von kunststoffgiessformen
DE69724121D1 (de) Verfahren zur sprühtrocknung von wasser-in-öl-emulsionen
DE59305971D1 (de) Verfahren zur entölung von rohlecithin
ATA124894A (de) Verfahren zur direktreduktion von eisenoxidhältigem material
DE69602534D1 (de) Verfahren zur verwendung von metallocenkatalysatoren
DE59808096D1 (de) Verfahren zur überwachung von bearbeitungsanlagen
DE69432333T2 (de) Verfahren zur Wasserbehandlung unter Verwendung von 5-allyldibenzosuberenol
DE69609082T2 (de) Verfahren zur behandlung von abfällen
DE69409666D1 (de) Verfahren unter verwendung von fluorwasserstoffbeständigen keramiken
DE59507436D1 (de) Verfahren zur direktreduktion von eisenoxidhältigem material
DE69525456D1 (de) Verfahren zur kultivierung von vogelzellen
DE69802904D1 (de) Verbessertes verfahren zur behandlung von aluminiummonohydratreichen bauxiten
ATE239696T1 (de) Verfahren zur behandlung von textilmaterialien
DE59503391D1 (de) Verfahren zur direktreduktion von eisenoxidhältigem material
DE69504707D1 (de) Verfahren zur wiederverwendung von verbundwerkstoffen
DE69429341T2 (de) Verfahren zur behandlung von flüssigkeiten
DE69533397D1 (de) Verfahren zur behandlung von hypertonie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee